Medicofarma Biotech Net Debt per Share
Net Debt per Share of Medicofarma Biotech (MDB.WA) as of Oct 29, 2026.
Get this data via API
Financial Data API
Net Debt per Share
0.00PLN
Last updated:
Net Debt per Share of Medicofarma Biotech is 2025 0.00 PLN. Net Debt per Share of Medicofarma Biotech was 2024 0.00 PLN. It decreases by % lower compared to the previous year.
The Medicofarma Biotech Net Debt per Share history
3 Years
10 Years
25 Years
Max
Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-0.00 PLN
Jan 1, 2019
0.00 PLN
Jan 1, 2020
0.00 PLN
Jan 1, 2021
-0.00 PLN
Jan 1, 2022
0.00 PLN
Jan 1, 2023
0.00 PLN
Jan 1, 2024
0.00 PLN
Jan 1, 2025
0.00 PLN
| YEAR | Net Debt per Share | YoY |
|---|---|---|
| 0.00PLN | — | |
| 0.00PLN | — | |
| 0.00PLN | — | |
| 0.00PLN | -100.00% | |
| -0.00PLN | -124.24% | |
| 0.00PLN | +50.00% | |
| 0.00PLN | -257.14% | |
| -0.00PLN | -61.11% | |
| -0.01PLN | +33.33% | |
| -0.00PLN | -12.90% | |
| -0.00PLN | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Medicofarma Biotech Stock analysis
What does Medicofarma Biotech do? Medicofarma Biotech SA is a biotechnology company based in Warsaw, Poland. The company is listed on the Warsaw Stock Exchange under the ticker MDB.WA and has an ISIN code of PLINBOK00010. It operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. Medicofarma Biotech SA completed its initial public offering (IPO) on November 27, 2008. The company focuses on the development and production of innovative medicines, medicinal products, and biotechnology products. Its research and development activities are conducted in laboratories located in Lublin and Poznan, Poland. The company's headquarters are situated in Warsaw, within the Mazowieckie region. Medicofarma Biotech SA's website is https://medicofarmabiotech.pl/. The company is engaged in the development of drugs, medical devices, and biotechnological products. It operates as a public company with a presence in multiple cities across Poland, including Warsaw, Lublin, and Poznan. The company's primary activities involve the research, development, and commercialization of biotechnology-based solutions for the healthcare sector. Medicofarma Biotech SA is registered in Poland and serves the broader European market with its products and services. Medicofarma Biotech is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Medicofarma Biotech stock
On Eulerpool you can find the complete historical development of Net Debt per Share Medicofarma Biotech since 2006 – with annual values, charts, and detailed analysis.
Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Other — Medicofarma Biotech
All Key Metrics — Medicofarma Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth